Dr. Pascal Vranckx is a member of the Faculty at Hasselt University in the Medicine and Life Sciences department in Hasselt Belgium. In this video Dr. Vranckx discusses the GLOBAL LEADERS trial. A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation.Link to Abstract-https://clinicaltrials.gov/ct2/show/results/NCT01813435?recrs=e&cond=Heart&phase=23&lupd_s=01%2F01%2F2019&lupd_e=11%2F24%2F2021&draw=4Abstract:Anti-platelet medicine is commonly prescribed after a stent surgery to prevent blood from clotting. The primary goal of this research is to see if there is a better pharmacological strategy for preventing blood clots while reducing the amount of problems.There are two treatment options:Study group: 1 month of dual antiplatelet medication (ticagrelor plus aspirin) followed by 23 months of ticagrelor alone ORStandard medication (ticagrelor or clopidogrel coupled with aspirin for 12 months, then aspirin alone indefinitely) was used in the control group.Description in detail:The goal of the study is to see if 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy is better than 12 months of stents in all-comers patients undergoing percutaneous coronary intervention (PCI) under standardised treatment (including the BioMatrix family of drug-eluting stents and bivalirudin) in terms of all-cause mortality or non-fatal new Q-wave myocardial infarction.The study will be undertaken in roughly 60-80 interventional cardiology centers in Europe, North America, South America, and Asia-Pacific. It will be an investigator-initiated, prospective randomised, multi-centre, multi-national, open-label experiment. Patients will be randomly assigned to either the study or the reference treatment method in a 1:1 ratio.Prior to PCI, randomization will take place during the index procedure. The participants will be divided into two groups: those with stable coronary artery disease (CAD) and those with acute coronary syndrome (ACS). - Cardiology - 596_600c9efaa3c99

Pascal Vranckx MD- GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Pascal Vranckx MD- GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

6 months
12 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Dr. Pascal Vranckx is a member of the Faculty at Hasselt University in the Medicine and Life Sciences department in Hasselt Belgium. In this video Dr. Vranckx discusses the GLOBAL LEADERS trial. A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation.

Link to Abstract-
https://clinicaltrials.gov/ct2/show/results/NCT01813435?recrs=e&cond=Heart&phase=23&lupd_s=01%2F01%2F2019&lupd_e=11%2F24%2F2021&draw=4

Abstract:
Anti-platelet medicine is commonly prescribed after a stent surgery to prevent blood from clotting. The primary goal of this research is to see if there is a better pharmacological strategy for preventing blood clots while reducing the amount of problems.

There are two treatment options:

Study group: 1 month of dual antiplatelet medication (ticagrelor plus aspirin) followed by 23 months of ticagrelor alone OR

Standard medication (ticagrelor or clopidogrel coupled with aspirin for 12 months, then aspirin alone indefinitely) was used in the control group.

Description in detail:

The goal of the study is to see if 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy is better than 12 months of stents in all-comers patients undergoing percutaneous coronary intervention (PCI) under standardised treatment (including the BioMatrix family of drug-eluting stents and bivalirudin) in terms of all-cause mortality or non-fatal new Q-wave myocardial infarction.

The study will be undertaken in roughly 60-80 interventional cardiology centers in Europe, North America, South America, and Asia-Pacific. It will be an investigator-initiated, prospective randomised, multi-centre, multi-national, open-label experiment. Patients will be randomly assigned to either the study or the reference treatment method in a 1:1 ratio.

Prior to PCI, randomization will take place during the index procedure. The participants will be divided into two groups: those with stable coronary artery disease (CAD) and those with acute coronary syndrome (ACS).

Up Next Autoplay